Stocks · News reference
Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See what other analysts think about these stocks.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Salesforce Inc (NYSE: CRM) stock rose on good Q2 results and raised FY27 guidance, while other tech stocks saw gains in early trading.Salesforce (NYSE: CRM) jumps on strong Q2 results and raised guidance, tech stocks up in pre-market trading.
Read original at benzingaLumentum CEO Michael Hurlston sold 6,185 shares worth $5.1 million on August 19 to cover tax withholding obligations from restricted stock unit vesting. This was a non-discretionary transaction and does not reflect his view on the stock. Hurlston retains 112,794 shares valued at $93.35 million. The stock has delivered a 602% one-year return, and the company is guiding for $1.25 billion in September quarter revenue with 39.5-40.5% margins, hitting its target model early amid strong demand for optical and photonic products.
Read original at the-motley-foolStock futures mixed, Nasdaq 100 down 100 points. Applied Optoelectronics falls after announcing $600M offering. Other pre-market losers include RFAI, ZSTK, ZKH, JMIA, VALN, MFI, COHR, SNDK, AXTI, ASTL, LITE, STX.
Read original at benzingaTop Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.
Read original at benzingaNeedham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $56.
Read original at benzinga